Results from samples of the Hong Thai Herbal Inhaler, Formula 2, revealed that the product failed to meet quality standards. - Photo: The Nation/ANN
BANGKOK: The Thai Food and Drug Administration (FDA) has issued an official announcement regarding the results of laboratory testing on herbal medicinal products.
Samples of the Hong Thai Herbal Inhaler, Formula 2, registration number G 309/62, produced by Hong Thai Panich, were collected for laboratory analysis by the Department of Medical Sciences.
The analytical results revealed that the product failed to meet quality standards under the test for microbial contamination, specifically exceeding limits in Total Aerobic Microbial Count, Total Combined Yeasts and Mould Count, and the detection of Clostridium spp.
This constitutes a violation under the Notification of the Ministry of Public Health on Standards, Purity, and Other Critical Characteristics Affecting Product Quality.
The herbal product had been registered or notified in 2021, and in order to protect consumers, the FDA has deemed it necessary to make the inspection results public.
The FDA therefore advises the public to exercise caution when purchasing or using this herbal product.
The agency is currently considering legal action against the responsible parties in accordance with the law. - The Nation/ANN
